Activation of the phosphatase PP2A has been shown to reduce abnormal phosphorylation of tau in the brain and ameliorate AD pathology (150, 151), suggesting that PP2A phosphatase activators could likely restore physiological levels of tau phosphorylation in patients. Here, PTPA is linked to Alzheimer disease.